Trevi Therapeutics Inc’s filing revealed that its Chief Scientific Officer SCIASCIA THOMAS unloaded Company’s shares for reported $17365.0 on Mar 25 ’25. In the deal valued at $6.60 per share,2,631 shares were sold. As a result of this transaction, SCIASCIA THOMAS now holds 221,373 shares worth roughly $1.43 million.
Then, GOOD JENNIFER L sold 5,263 shares, generating $34,625 in total proceeds. Upon selling the shares at $6.58, the President & CEO now owns 213,313 shares.
Before that, GOOD JENNIFER L bought 5,263 shares. Trevi Therapeutics Inc shares valued at $34,625 were divested by the Officer at a price of $6.58 per share.
Raymond James upgraded its Trevi Therapeutics Inc [TRVI] rating to a Strong buy from a an Outperform in a research note published on March 10, 2025; the price target was increased to $29 from $9. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early March has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright also remained covering TRVI and reiterated its “Buy” recommendation on December 12, 2024.
Price Performance Review of TRVI
On Tuesday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock fall -3.66% to $6.45. Over the last five days, the stock has lost -1.90%. Trevi Therapeutics Inc shares have risen nearly 56.67% since the year began. Nevertheless, the stocks have risen 121.06% over the past one year. While a 52-week high of $7.39 was reached on 03/10/25, a 52-week low of $2.30 was recorded on 01/22/25. SMA at 50 days reached $6.17, while 200 days put it at $4.09.
Levels Of Support And Resistance For TRVI Stock
The 24-hour chart illustrates a support level at 6.29, which if violated will result in even more drops to 6.13. On the upside, there is a resistance level at 6.72. A further resistance level may holdings at 6.99. The Relative Strength Index (RSI) on the 14-day chart is 51.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.72%. Stochastics %K at 44.86% indicates the stock is a holding.
The most recent change occurred on August 30, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.
